Characteristics of patients with APL
| No. . | Sex/age, y . | Diagnosis . | WBC count, × 109/L . | Hb level, g/L . | Plt count, × 109/L . | Blasts, BM% . | PT, sec . | APTT, sec . | TT, sec . | Fbg level, g/L . | D-dimer level, μg/mL . | Hemorrhage . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/20 | M3/bcr1 | 5.02 | 87.5 | 10.5 | 85.5 | 15.9 | 23.5 | 19.1 | 0.77 | 2 | + |
| 2 | M/34 | M3/bcr1 | 7.37 | 106 | 11.3 | 88.5 | 18.0 | 27.2 | 18.5 | 0.63 | 6.7 | + |
| 3 | F/54 | M3/bcr1 | 19.73 | 68.2 | 29.4 | 90 | 14.6 | 20.8 | 16.2 | 1.65 | 0.9 | + |
| 4 | M/35 | M3/bcr1 | 46.3 | 71.3 | 14.5 | 92 | 14.2 | 23.2 | 17.5 | 0.86 | 0.6 | + |
| 5 | F/47 | M3/bcr3 | 1.43 | 53.6 | 32.1 | 89.5 | 13.9 | 31.9 | 14 | 2.91 | 0.6 | + |
| 6 | M/49 | M3v/bcr2 | 2 | 74 | 28 | 96.5 | 13.6 | 24.7 | 28.2 | 4.24 | 2 | − |
| 7 | M/45 | M3/bcr1 | 3 | 57 | 15 | 86 | 13.3 | 37.2 | 16.9 | 4.68 | 4.7 | + |
| 8 | F/38 | M3v/bcr2 | 96.8 | 88 | 14 | 81 | 16.4 | 23.7 | 20 | 1.37 | 4 | + |
| 9 | F/45 | M3/bcr1 | 35.1 | 60.4 | 19.8 | 83.5 | 16.5 | 24.3 | 20.4 | 0.94 | 1.2 | + |
| 10 | F/52 | M3/bcr1 | 4.1 | 72 | 12 | 93.5 | 13.4 | 23.3 | 25.8 | 1.89 | 4 | + |
| 11 | F/44 | M3/bcr3 | 0.8 | 5 | 31 | 94 | 14.9 | 34.1 | 28.6 | 1.47 | 4 | − |
| 12 | M/38 | M3/bcr1 | 23 | 101 | 10 | 82 | 12.3 | 20.2 | 29.2 | 1.34 | 3.6 | + |
| 13 | M/54 | M3/bcr3 | 1.7 | 63 | 3 | 88.5 | 12.4 | 24.6 | 21.9 | 3.47 | 1 | + |
| 14 | F/30 | M3/bcr1 | 3.11 | 60 | 51 | 86.5 | 13.6 | 23.5 | 19.4 | 0.44 | 0.5 | + |
| 15 | F/37 | M3/bcr3 | 1.1 | 35 | 7 | 86 | 15.4 | 28.1 | 41.2 | 2.19 | 2 | + |
| 16 | F/42 | M3/bcr1 | 0.4 | 76 | 68 | 86.5 | 13.4 | 25.9 | 26.6 | 4.49 | 4 | + |
| Reference range | 4-10 | 110-170 | 100-300 | 0-0.4 | 10-15 | 20-40 | 11-20 | 2-4 | 0-0.3 |
| No. . | Sex/age, y . | Diagnosis . | WBC count, × 109/L . | Hb level, g/L . | Plt count, × 109/L . | Blasts, BM% . | PT, sec . | APTT, sec . | TT, sec . | Fbg level, g/L . | D-dimer level, μg/mL . | Hemorrhage . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/20 | M3/bcr1 | 5.02 | 87.5 | 10.5 | 85.5 | 15.9 | 23.5 | 19.1 | 0.77 | 2 | + |
| 2 | M/34 | M3/bcr1 | 7.37 | 106 | 11.3 | 88.5 | 18.0 | 27.2 | 18.5 | 0.63 | 6.7 | + |
| 3 | F/54 | M3/bcr1 | 19.73 | 68.2 | 29.4 | 90 | 14.6 | 20.8 | 16.2 | 1.65 | 0.9 | + |
| 4 | M/35 | M3/bcr1 | 46.3 | 71.3 | 14.5 | 92 | 14.2 | 23.2 | 17.5 | 0.86 | 0.6 | + |
| 5 | F/47 | M3/bcr3 | 1.43 | 53.6 | 32.1 | 89.5 | 13.9 | 31.9 | 14 | 2.91 | 0.6 | + |
| 6 | M/49 | M3v/bcr2 | 2 | 74 | 28 | 96.5 | 13.6 | 24.7 | 28.2 | 4.24 | 2 | − |
| 7 | M/45 | M3/bcr1 | 3 | 57 | 15 | 86 | 13.3 | 37.2 | 16.9 | 4.68 | 4.7 | + |
| 8 | F/38 | M3v/bcr2 | 96.8 | 88 | 14 | 81 | 16.4 | 23.7 | 20 | 1.37 | 4 | + |
| 9 | F/45 | M3/bcr1 | 35.1 | 60.4 | 19.8 | 83.5 | 16.5 | 24.3 | 20.4 | 0.94 | 1.2 | + |
| 10 | F/52 | M3/bcr1 | 4.1 | 72 | 12 | 93.5 | 13.4 | 23.3 | 25.8 | 1.89 | 4 | + |
| 11 | F/44 | M3/bcr3 | 0.8 | 5 | 31 | 94 | 14.9 | 34.1 | 28.6 | 1.47 | 4 | − |
| 12 | M/38 | M3/bcr1 | 23 | 101 | 10 | 82 | 12.3 | 20.2 | 29.2 | 1.34 | 3.6 | + |
| 13 | M/54 | M3/bcr3 | 1.7 | 63 | 3 | 88.5 | 12.4 | 24.6 | 21.9 | 3.47 | 1 | + |
| 14 | F/30 | M3/bcr1 | 3.11 | 60 | 51 | 86.5 | 13.6 | 23.5 | 19.4 | 0.44 | 0.5 | + |
| 15 | F/37 | M3/bcr3 | 1.1 | 35 | 7 | 86 | 15.4 | 28.1 | 41.2 | 2.19 | 2 | + |
| 16 | F/42 | M3/bcr1 | 0.4 | 76 | 68 | 86.5 | 13.4 | 25.9 | 26.6 | 4.49 | 4 | + |
| Reference range | 4-10 | 110-170 | 100-300 | 0-0.4 | 10-15 | 20-40 | 11-20 | 2-4 | 0-0.3 |
The main clinical and laboratory features of 16 patients with newly diagnosed APL at the moment of BM aspiration were reported. Hemorrhage was manifested as mucosal bleeding, spontaneous ecchymoses, petechiae, hematemesis, hematuria, melena, or menorrhagia.
WBC indicates white blood cells; Hb, hemoglobin; Plt, platelet; Blasts, promyelocytes + blasts; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; Fbg, fibrinogen; and bcr, breakpoint cluster region (bcr1 = intron 6, bcr2 = exon 6, bcr3 = intron3).